Stockreport

Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results

Trillium Therapeutics Inc. - Common Shares  (TRIL) 
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am Check Earnings Report
PDF Increased focus on T cell lymphoma in lead program, TTI-621 Initiated dosing of TTI-622 (SIRPaFc IgG4) in phase 1a/1b clinical trial Recruited Dr. Yaping Shou as Chief M [Read more]